| HOME >> BIOLOGY >> TECHNOLOGY |
Importantly, the Life Sciences Initiative encourages life sciences industry leaders, such as EMD Serono, to invest, stimulate and strengthen the economy in the Commonwealth.
"I would like to thank Governor Patrick for his unwavering commitment to strengthening Massachusetts' reputation as a global leader in science and medicine," says Firouz. "The partnership and commitment of Governor Patrick, Senate President Therese Murray, and Speaker of the House Salvatore DiMasi to make the Life Sciences Initiative a reality has been the foundation of the overall life sciences development plan that will help ensure that Massachusetts' existing life sciences companies stay and thrive in the state, and that new life sciences companies come to Massachusetts to further enhance our position at the forefront of healthcare."
About EMD Serono, Inc.
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R) (somatropin (rDNA origin) for injection), Serostim(R) (somatropin (rDNA origin) for injection) and Zorbtive(TM) (somatropin (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 850 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.
For more information, please visit '/>"/>
| SOURCE EMD Serono, Inc. Copyright©2008 PR Newswire. All rights reserved |